newsfilter
← Earnings
Earnings Releases·

Instil Bio — Third Quarter 2026 Earnings Summary

Instil Bio reported a net loss of $4.2 million for the third quarter of 2026 and $13.0 million for the first nine months of the year. As of September 30, 2026, the company held approximately $67.1 million in cash and investments, which is expected to fund operations through 2027. Research and development expenses decreased significantly to $0.2 million for the quarter and $1.2 million for the nine-month period compared to prior year figures. The company also corrected immaterial errors in previously issued financial statements related to property taxes and tenant reimbursements.

Company
INSTIL BIO INC
Sector
Healthcare
Industry
Biotechnology